PHARMA - Relationships

Relationships Table

Entities - Color - Target Drug Disease Lo Med Hi
Brain Cancer 1,542 Disease Target Kallikrein-8 19 1 0.01 -0.97 0.05 0.68
Cathepsin G 1,613 Target Target Kallikrein-8 19 1 0.01 -0.97 0.05 0.68
Arthritis 128,324 Disease Target Kallikrein-8 19 1 0.00 -0.97 0.05 0.57
Benign Prostatic Hyperplasia 10,026 Disease Target Kallikrein-8 19 1 0.00 -0.97 0.05 0.63
Tissue-Type Plasminogen Activator 5,020 Target Target Kallikrein-8 19 1 0.00 -0.97 0.05 0.64
Lung Cancer 91,416 Disease Drug Kaad-Cyclopamine 19 1 0.00 -0.97 0.05 0.58
Androgen Receptor 12,918 Target Drug Kaad-Cyclopamine 19 1 0.00 -0.97 0.05 0.62
Diabetes 332,602 Disease Drug Kaad-Cyclopamine 19 1 0.00 -0.97 0.05 0.55
CD68 6,424 Target Target Eotaxin-2/CCL24 19 1 0.00 -0.97 0.05 0.64
Skin Disease 6,955 Disease Target Eotaxin-2/CCL24 19 1 0.00 -0.97 0.05 0.64
CD4 112,219 Target Target Eotaxin-2/CCL24 19 2 0.00 -0.95 0.11 0.59
CCL7 274 Target Target Eotaxin-2/CCL24 19 1 0.01 -0.97 0.05 0.73
CCL4 5,638 Target Target Eotaxin-2/CCL24 19 1 0.00 -0.97 0.05 0.64
Tuberculosis 146,217 Disease Target Eotaxin-2/CCL24 19 1 0.00 -0.97 0.05 0.57
Infection 766,637 Disease Target Eotaxin-2/CCL24 19 2 0.00 -0.95 0.11 0.55
Eotaxin 2,457 Target Target Eotaxin-2/CCL24 19 19 0.09 -0.22 1.00 0.76
Arthritis 128,324 Disease Target Eotaxin-2/CCL24 19 1 0.00 -0.97 0.05 0.57
CCL2 3,560 Target Target Eotaxin-2/CCL24 19 2 0.01 -0.95 0.11 0.67
Eotaxin-3/CCL26 26 Target Target Eotaxin-2/CCL24 19 10 0.45 -0.54 0.53 0.94
Colon Cancer 30,064 Disease Target Complement Decay-Accelerating Factor 19 1 0.00 -0.97 0.05 0.60
CD4 112,219 Target Target Complement Decay-Accelerating Factor 19 1 0.00 -0.97 0.05 0.57
Metastatic Breast Cancer 9,288 Disease Drug Aralen (Chloroquine)- FDA 19 1 0.00 -0.97 0.05 0.63
Cancer 1,053,491 Disease Drug Aralen (Chloroquine)- FDA 19 3 0.00 -0.92 0.16 0.55
Atridox (Doxycycline Hyclate)- FDA 38 Drug Drug Aralen (Chloroquine)- FDA 19 2 0.07 -0.92 0.11 0.84
Cancer 1,053,491 Disease Drug Amitiza (Lubiprostone)- FDA 19 1 0.00 -0.97 0.05 0.53
Nausea 42,627 Disease Drug Amitiza (Lubiprostone)- FDA 19 6 0.01 -0.83 0.32 0.64
Diarrhea 51,986 Disease Drug Amitiza (Lubiprostone)- FDA 19 7 0.01 -0.79 0.37 0.63
Dyspnea 24,781 Disease Drug Amitiza (Lubiprostone)- FDA 19 1 0.00 -0.97 0.05 0.60
Headache 50,687 Disease Drug Amitiza (Lubiprostone)- FDA 19 2 0.00 -0.95 0.11 0.60
CD1A 2,739 Target Target AMAC-1 19 1 0.00 -0.97 0.05 0.66
CD68 6,424 Target Target AMAC-1 19 1 0.00 -0.97 0.05 0.64
Graft Versus Host Disease 15,741 Disease Target AMAC-1 19 1 0.00 -0.97 0.05 0.62
CD4 112,219 Target Target AMAC-1 19 1 0.00 -0.97 0.05 0.57
Diabetes 332,602 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.55
Poisoning 53,779 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.59
Osteoarthritis 36,287 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.60
Cancer 1,053,491 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.53
Prostate Cancer 71,064 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.58
Osteoporosis 46,215 Disease Target ALK Phos 19 2 0.00 -0.95 0.11 0.61
Pneumonia 81,521 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.58
Renal Failure 73,993 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.58
Anemia 81,663 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.58
Diabetes 332,602 Disease Target 464.1 19 1 0.00 -0.97 0.05 0.55
744.1 22 Target Target 464.1 19 1 0.05 -0.95 0.05 0.83
Carcinoma 433,099 Disease Target 464.1 19 1 0.00 -0.97 0.05 0.54
Cancer 1,053,491 Disease Target 464.1 19 2 0.00 -0.95 0.11 0.54
Prostate Cancer 71,064 Disease Target 464.1 19 1 0.00 -0.97 0.05 0.58
Acute Promyelocytic Leukemia 4,780 Disease Target 464.1 19 1 0.00 -0.97 0.05 0.65
Eotaxin 2,457 Target Target 464.1 19 1 0.00 -0.97 0.05 0.66
Renal Failure 73,993 Disease Target 464.1 19 1 0.00 -0.97 0.05 0.58